Tritonix.ai

News / Taiwan / cnyes

JieLiKang to Debut on Emerging Stock Market on Aug 31, Targeting Soft Tissue Repair Market

Health Technology · Biotechnology · cnyes · 2026-08-24

7686

Biotech firm JieLiKang (7686) is set to list on the emerging stock market on August 31, leveraging its proprietary LipoShell and HeliBarb platforms to capture growth in breast reconstruction and medical aesthetics.

What Happened

Market Debut: JieLiKang (7686) has announced its official listing on the emerging stock market scheduled for August 31, with a current paid-in capital of NT$501 million. Chairman Tseng Yu-chia stated that the company is leveraging its core technological platforms to address growing demands in breast reconstruction and medical aesthetics.

Core Technology Platforms: The company utilizes its LipoShell platform for soft tissue reconstruction, employing biodegradable materials to facilitate tissue regeneration. Having completed large animal trials, the company aims to initiate human clinical trials by the first quarter of 2028, while the HeliBarb platform focuses on providing stable support through a patented non-barbed spiral design.

Aesthetics Product Pipeline: The first product under the HeliBarb platform, the JOUVENCE bio-absorbable lifting thread, is currently undergoing regulatory review in Taiwan. The product is designed to provide uniform and stable lifting support, marking a key milestone in the company's product development strategy.

International Expansion: Chairman Tseng noted that JOUVENCE is primarily targeting the Japanese market, with a potential launch expected as early as next year. Beyond Japan, the company is actively planning to expand its footprint into Southeast Asian markets, including Thailand and the Philippines, to drive future growth.

Read original

More in Health Technology

Medigen Vaccine Biologics Partners with Global and Local Firms for Next-Gen Enterovirus Vaccine

Health Technology · cnyes · 2026-08-24

Medigen Vaccine Biologics has launched a dual-track strategy to develop a multi-valent enterovirus vaccine by partnering with international and local experts.

6547, 6939

PharmaEssentia's Ropeg Receives Japanese Approval for All ET Patients

Health Technology · cnyes · 2026-08-24

PharmaEssentia has secured Japanese regulatory approval for its drug Ropeg to treat all patients with essential thrombocythemia, marking a significant milestone.

6446

QIC: Taiwan Biotech Sector Poised for Growth as Capital Shifts from AI-Driven Tech Stocks

Health Technology · economic_daily · 2026-08-24

QIC CEO Felix Li suggests that as AI and semiconductor valuations peak, capital rotation into Taiwan's resilient biotech sector could trigger exponential market cap growth.

6446, 6712, 6841, 6891, 7850

Latest in Taiwan

Copper Prices Surge: First Copper Rallies Above Key Moving Averages

Non-Energy Minerals · economic_daily · 2026-08-24

Driven by elevated global copper prices, First Copper shares have seen a significant surge in trading volume and successfully cleared all major moving averages.

Niche Memory Price Hikes Drive Elite Semiconductor to Daily Limit

Electronic Technology · economic_daily · 2026-08-24

Elite Semiconductor is surging to its daily limit as supply shortages in the niche memory market drive product prices higher and attract heavy trading volume.

LuxNet Reclaims Moving Averages as Market Speculates on Rebound

Electronic Technology · economic_daily · 2026-08-24

LuxNet shares have staged a strong technical rebound, reclaiming all key moving averages and sparking market debate over the catalysts behind the rally.

Fubon Financial Reports Record H1 Profit for Life Insurance Unit on Strong Stock Market Gains

Finance · cnyes · 2026-08-24

Fubon Financial's life insurance arm posted record-breaking H1 profits, driven by a 65% return on its Taiwan stock portfolio and a focus on AI-led growth.

2881